Priyanka Chopra Returns To Citadel Spy-Verse, Shares New Post: "Nadia Is Back" | news.google.com • |
Citadel Season 2: Priyanka Chopra Shares Glimpse From The Sets of Spy Series | news.google.com • |
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates | news.google.com • |
Fed Day: 5 Things Investors Need to Know for FOMC Meeting | zacks.com • |
SPY: Equity And Bond Markets Flash Conflicting Signals On Recession Risk | seekingalpha.com • |
SPY: 3 Paths for Stocks AFTER Fed Meeting | news.google.com • |
Dividend | Date |
---|---|
1.75902 | 2024-06-21 |
1.59494 | 2024-03-15 |
1.90607 | 2023-12-15 |
1.58317 | 2023-09-15 |
1.63837 | 2023-06-16 |
1.5062 | 2023-03-17 |
-
-
-
-
-
-
-
-
-
-
Look at the massive amount of Puts expiring today. And this board is full of Bearish sentimentβ¦.
-
-
Aaawwwf!!! Overshott!!! Powell and the crew jacked everything up!!! Those job gains arenβt, inflation!!! Folks stacking inventoryβ¦ whooops!! Sell at 5% of price paid!! Inventory level zero!!
-
$PTC Therapeutics(PTCT.US)$ Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date. -
$PTC Therapeutics(PTCT.US)$ Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
-
SPY: Equity And Bond Markets Flash Conflicting Signals On Recession Risk
seekingalpha.com • -
SPY: 3 Paths for Stocks AFTER Fed Meeting
news.google.com • -
New Gamma ETF Mixes Large-Cap & T-Bill Exposure
etftrends.com • -
Market Internals Signal Upside Breakout
forbes.com • -
SPY ETF Update, 9/17/2024
news.google.com • -
5 Stocks That Led the SPY ETF to Log Its Best Week in 2024
news.google.com • -
S&P 500 Snapshot: Market Bounces Back
etftrends.com • -
(SPY) Pivots Trading Plans and Risk Controls
news.google.com • -
SPY: The Market May Be Wrong Now
seekingalpha.com • -
What VIX Tells Us About Opportunity in Low Vol ETFs
etftrends.com • -
S&P 500 Snapshot: Market Bounces Back- Advisor Perspectives
news.google.com • -
SPY: CPI Tailwinds Already Priced In
seekingalpha.com • -
Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
marketbeat.com • -
These 2 REITs Are Still Great Buys After The Real Estate Rally
seekingalpha.com • -
If You Can Only Buy One Stock, It Better Be One of These 3 Names
247wallst.com • -
2 Very Overrated And 2 Very Underrated Big Dividend Funds
seekingalpha.com • -
Dividend Histories Help
seekingalpha.com •